A Phase II trial of 2X-121 in recurrent ovarian cancer
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2018
At a glance
- Drugs 2X 121 (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 01 Nov 2018 According to a Medical Prognosis Institute media release, this trial is expected to commence in Q1 2019.
- 27 Aug 2018 According to a Medical Prognosis Institute media release, the Oncology Venture along with the Medical Prognosis Institute has received an Investigational Device Exemption (IDE) and its Investigational New Drug Application (IND) approval from the US FDA to initiate this study in USA and Germany.
- 03 Jul 2018 New trial record